26 Results for "

myopathy

" in MedChemExpress (MCE) Product Catalog:
Products (26)

26 Results for "myopathy" in MCE Product Catalog:

14
14 Publications Verification
Cat. No.: HY-113071A
CAS No.: 2618458-93-6
Purity:  ≥98.0%
Synonyms: MVA lithium salt
Mevalonic acid (MVA) lithium salt is a precursor substance of the mevalonate pathway, which is essential for cell growth and proliferation. Mevalonic acid lithium salt is effective in inhibiting Simvastatin (HY-17502)-induced decrease in C2C12 cell viability in vitro. Mevalonic acid lithium salt can be used in studies of myopathy and heart failure .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-107855
CAS No.: 674-26-0
Purity:  99.15%
Synonyms: (±)-Mevalonolactone; Mevalolactone
DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy . DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling [2][4].
loading...
    loading...
Cat. No.: HY-P3502
CAS No.: 1841136-73-9
Synonyms: RA101495; RA3193
Target:  

Complement System

Research Areas:  

Inflammation/Immunology

Zilucoplan (RA101495), a 15-amino acid macrocyclic peptide, is a potent complement component 5 (C5) inhibitor. Zilucoplan can be used in research of immune-mediated necrotising myopathy (IMNM) .
loading...
    loading...
Cat. No.: HY-113071
CAS No.: 150-97-0
Synonyms: MVA
Mevalonic acid (MVA) is a precursor substance of the mevalonate pathway, which is essential for cell growth and proliferation. Mevalonic acid is effective in inhibiting Simvastatin (HY-17502)-induced decrease in C2C12 cell viability in vitro. Mevalonic acid can be used in studies of myopathy and heart failure .
loading...
    loading...
Cat. No.: HY-113152
CAS No.: 2416-19-5
Purity:  ≥98.0%
Hypogeic acid is a fatty acid and endogenous metabolite, with a concentration of 50 mg/mL in ethanol. The plasma level of Hypogeic acid is negatively correlated with the prevalence of interstitial lung disease in idiopathic inflammatory myopathy. Hypogeic acid can be used in studies related to idiopathic inflammatory myopathy .
loading...
    loading...
Cat. No.: HY-135700
CAS No.: 19115-49-2
Purity:  ≥98.0%
Mevalonolactone is an intermediate metabolite in the eukaryotic mevalonate pathway, serving as the stable δ-lactone form of mevalonate with oral activity. Mevalonolactone exhibits binding affinity for ZNF384 (Ka = 12.6 μM) and inhibitory activity against aconitase (aconitase). Mevalonolactone promotes the nuclear localization of ZNF384 and enhances its binding to the GGPPS promoter. Mevalonolactone induces insulin resistance, disrupts glucose and lipid metabolism, enhances the isoprenylation of K-Ras, and inhibits the activation of the insulin signaling pathway. Mevalonolactone inhibits polypeptide synthesis of HMG-CoA reductase in isolated rat hepatocytes, promotes its degradation, and reduces its enzymatic activity. Mevalonolactone impairs mitochondrial function in rat brains. Mevalonolactone promotes the development of metabolically unhealthy obesity. Mevalonolactone can be used in research related to metabolically abnormal obesity, mevalonic aciduria, HMGCR-related limb-girdle myopathy, and statin-induced myopathy .
loading...
    loading...
Cat. No.: HY-112597A
CAS No.: 1604815-32-8
Purity:  99.89%
Synonyms: REN001; HPP593
Target:  

PPAR

Research Areas:  

Inflammation/Immunology

Mavodelpar (REN001) is a selective PPARδ agonist. Mavodelpar suppresses glomerular injury and renal fibrosis. Mavodelpar can be used for the research of primary mitochondrial myopathies (PMM) and long-chain fatty acid oxidation disorders (LC-FAOD) . Mavodelpar is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
loading...
    loading...
Cat. No.: HY-134377
CAS No.: 2095128-20-2
Purity:  98.08%
Synonyms: ASP0367; MA-0211
Target:  

PPAR

Research Areas:  

Metabolic Disease

Bocidelpar (ASP0367; MA-0211) is a selective, orally active PPARδ modulator. Bocidelpar activates the PPARδ downstream signaling pathway, upregulates the expression of target genes such as ABCA1 and ACAA2. Bocidelpar then promotes fatty acid oxidation (FAO) and mitochondrial biogenesis, and improves mitochondrial dysfunction. Bocidelpar can improve mitochondrial biogenesis and function in muscle cells. Bocidelpar is mainly used in the study of mitochondrial dysfunction diseases such as primary mitochondrial myopathy (PMM) and Duchenne muscular dystrophy (DMD) .
loading...
    loading...
Cat. No.: HY-160821A
CAS No.: 335275-62-2
Synonyms: ManNAc-6P sodium salt
Target:  

Endogenous Metabolite

Research Areas:  

Others

N-Acetylmannosamine 6-phosphate sodium salt is a NanR modulator and an intermediate in the sialic acid pathway. N-Acetylmannosamine 6-phosphate sodium salt disrupts the binding of NanR to the promoter regions of nanAT and nanE, and prevents NanR-mediated transcriptional repression of these loci. N-Acetylmannosamine 6-phosphate sodium salt acts as a key precursor for sialic acid biosynthesis, participating in this process via Neu5Ac-9-P synthase. N-Acetylmannosamine 6-phosphate sodium salt can be used in research related to GNE myopathy .
loading...
    loading...
Cat. No.: HY-132583A
Synonyms: DYM101 sodium
Target:  

Dynamin

Research Areas:  

Cardiovascular Disease

IONIS-DNM2-2.5Rx sodium is an antisense agent targeting dynamin 2, and has the potential for the research of centronuclear myopathy (CNM) .
loading...
    loading...
Cat. No.: HY-P3502A
Synonyms: RA101495 TFA; RA3193 TFA
Target:  

Complement System

Research Areas:  

Inflammation/Immunology

Zilucoplan TFA (RA101495), a 15-amino acid macrocyclic peptide, is a potent complement component 5 (C5) inhibitor. Zilucoplan TFA can be used in research of immune-mediated necrotising myopathy (IMNM) .
loading...
    loading...
Cat. No.: HY-113071C
CAS No.: 32451-23-3
Synonyms: (S)-MVA
(S)-Mevalonic acid is the isomer of Mevalonic acid (HY-113071). Mevalonic acid ((S)-DCIT) is a precursor substance of the mevalonate pathway, which is essential for cell growth and proliferation. Mevalonic acid is effective in inhibiting Simvastatin (HY-17502)-induced decrease in C2C12 cell viability in vitro. Mevalonic acid can be used in studies of myopathy and heart failure .
loading...
    loading...
Cat. No.: HY-132583
CAS No.: 2857839-05-3
Synonyms: DYM101
Target:  

Dynamin

Research Areas:  

Cardiovascular Disease

IONIS-DNM2-2.5Rx (DYM101) is an antisense agent targeting dynamin 2. IONIS-DNM2-2.5Rx has the potential for the research of centronuclear myopathy (CNM) .
loading...
    loading...
Cat. No.: HY-107855R
CAS No.: 674-26-0
Synonyms: (±)-Mevalonolactone (Standard); Mevalolactone (Standard)
DL-Mevalonolactone (Standard) is the analytical standard of DL-Mevalonolactone. This product is intended for research and analytical applications. DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy . DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling .
loading...
    loading...
Cat. No.: HY-113071AR
CAS No.: 2618458-93-6
Synonyms: MVA lithium salt (Standard)
Mevalonic acid lithium salt (Standard) is the analytical standard of Mevalonic acid lithium salt. This product is intended for research and analytical applications. Mevalonic acid (MVA) lithium salt is a precursor substance of the mevalonate pathway, which is essential for cell growth and proliferation. Mevalonic acid lithium salt is effective in inhibiting Simvastatin (HY-17502)-induced decrease in C2C12 cell viability in vitro. Mevalonic acid lithium salt can be used in studies of myopathy and heart failure .
loading...
    loading...
Cat. No.: HY-168007
Target:  

p97

Research Areas:  

Neurological Disease Cancer

NSC804515 is an inhibitor of wild-type and R155H mutant p97/VCP ATPase, with an IC50 of about 15 nM for both targets. NSC804515 acts as an antiproliferative agent, disrupts the function of the ubiquitin-proteasome system, induces UbG76V-GFP accumulation, and shows reduced inhibitory potency against p97 variants carrying P510S, K512N, N616F and F618S mutations. NSC804515 can be used in research related to cancer, inclusion body myopathy with early-onset Paget's disease and frontotemporal dementia, as well as familial amyotrophic lateral sclerosis .
loading...
    loading...
Cat. No.: HY-107855S2
CAS No.: 53771-22-5
Synonyms: (±)-Mevalonolactone-13C; Mevalolactone-13C
DL-Mevalonolactone- 13C ((±)-Mevalonolactone- 13C) is the 13C-labeled DL-Mevalonolactone (HY-107855). DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy. DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling.
loading...
    loading...
Cat. No.: HY-107855S4
CAS No.: 287111-36-8
Synonyms: (±)-Mevalonolactone-13C2; Mevalolactone-13C2
DL-Mevalonolactone- 13C2 ((±)-Mevalonolactone- 13C2) is the 13C-labeled DL-Mevalonolactone (HY-107855). DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy . DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling [2][4].
loading...
    loading...
Cat. No.: HY-W752587
CAS No.: 349553-98-6
Synonyms: (±)-Mevalonolactone-d4; Mevalolactone-d4
DL-Mevalonolactone-d4 ( (±)-Mevalonolactone-d4) is the deuterium labeled DL-Mevalonolactone (HY-107855). DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy . DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling .
loading...
    loading...
Cat. No.: HY-L118
200 compounds

Sodium channels conduct sodium ions (Na+) through a cell's plasma membrane that are the source of excitatory currents for the nervous system and muscle. Na channels are classified according to the trigger that opens the channel for such ions, i.e. either a voltage-change (Voltage-gated, voltage-sensitive, or voltage-dependent sodium channel also called VGSCs or Nav channel) or a binding of a substance (a ligand) to the channel (ligand-gated sodium channels). Dysfunction in voltage-gated sodium channels correlates with neurological and cardiac diseases, including epilepsy, myopathies, pain and cardiac arrhythmias. Sodium channel blockers are used in the treatment of cardiac arrhythmia, pain and convulsion.

MCE offers a unique collection of 200 sodium channel blocker and antagonists, all of which have the identified inhibitory effect on sodium channels. MCE Sodium Channel Blocker Library can be used for neurological and cardiac diseases drug discovery and sodium channel research.